Inherited Antithrombin Deficiency Causing Thrombophilia

Summary

Blood coagulation systems were studied in members of a family with remarkably high incidence of thrombo - embolic diseases. Thrombotic episodes most often occurred as deep venous thrombosis in the legs, with the first attack at the age of 10-25 years.

Pro coagulant factor activities were found within normal variation ranges.

Plasma antithrombin III (progressive antithrombin) activity was abnormally low in members with history of thrombosis and in some of their children, with an average level of about 50 per cent of normal.

Heparin resistance measured with plasma heparin thrombin time was increased in members with low antithrombin III, and plasma heparin cofactor activity was decreased.

The results strongly support the explanation that antithrombin III and heparin cofactor are one and the same plasma substance, and that deficiency of this antithrombin can cause a severe tendency to thrombosis.

The antithrombin deficiency seems to be inherited as an autosomal dominant trait.

• References

• 1 Aas K. Prokonvertin og konvertin. P. 21. Akad. Trykningssentral, Oslo 1952
• 2 Astrup T, Darling S. Measurement and properties of antithrombin. Acta physiol. scand. 4: 293 1942;
• 3 Astrup T, Darling S. Antithrombin and heparin. Acta physiol. scand. 5: 13 1943;
• 4 Astrup T, Müllertz S. The fibrin plate method for estimating fibrinolytic activity. Arch. Biochem. 40: 346 1952;
• 5 Blombach B, Blombach M. Purification of human and bovine fibrinogen. Ark. Kemi 10: 415 1956;
• 6 Borchgrevink C. F, Waaler B. A. The secondary bleeding time. Acta med. scand. 162: 361 1958;
• 7 Burstein M. Sur l’inactivation de la thrombine par le plasma héparine. Arch. int. Pharma-codyn. itfi: 285 1955;
• 8 Burstein M, Guinand A. Héparine et consommation de l’antithrombine. Arch. int. Pharma-codyn. 104: 435 1956;
• 9 Egeberg O. Assay of antihemophilic A, B and C factors by one-stage cephalin systems. Scand. J. clin. Lab. Invest. 13: 140 1961;
• 10 Egeberg O. Antihemophilic A factor (factor VIII) and fibrinogen in human blood. A study on the question of a closer connection between the levels of the two factors. Scand. J. clin. Lab. Invest. 14: 230 1962; a
• 11 Egeberg O. Changes in the coagulation system following major surgical operations. Acta med. scand. 171: 679 1962; b
• 12 Egeberg O. The effect of unspecific fever induction on the blood clotting system. Scand. J. J. clin. Lab. Invest. 14: 471 1962; c
• 13 Egeberg O. The effect of intramuscular blood injections on the blood clotting system. Scand. J. clin. Lab. Invest 14: 487 1962; d
• 14 Fell C, Ivanovic N, Johnson S. A, Seegers W. H. Differentiation of plasma antithrombin activities. Pros. Soc. exp. Biol. Med. 85: 199 1954;
• 15 Geranclas M. Die Thrombinaktivierung als Enzymprozeβ. Thrombos. Diathes. haemorrh. (Stuttg.) 4: 56 1960;
• 16 Godai H. G. Heparin tolerance and the plasma proteins. Scand. J. clin. Lab. Invest. 13: 314 1961;
• 17 Godai H. C. Simple syneresis procedure for fibrinogen assay. Scand. J. clin. Lab. Invest. 15: 531 1961;
• 18 Gormsen J. Koagulasjonsproblemer ved acut coronarthrombose. Thesis, Copenhagen 1957.
• 19 Hellem A. J. The adhesiveness of human blood platelets in vitro. Oslo University Press; Oslo: 1960
• 20 Hensen A, Loeliger E. A. Antithrombin III. Its metabolism and its function in blood coagulation. Thrombos. Diathes. haemorrh. (Stuttg.). 9, Suppl. 1 1963
• 21 Hjort P. F. Intermediate reactions in the coagulation of blood with tissue thromboplastin. Convertili, accelerili, prothrombinase. Scand. J. clin. Lab. Invest.. 9, Suppl. 27 1957
• 22 Hjort P. F, Rapaport S. I, Owren P. A. A simple one-stage prothrombin assay using Russell’s viper venom in cephalin suspension. J. Lab. clin. Med. 46: 89 1955;
• 23 Holger-Madsen T. Heparin resistance in acute coronary occlusion measured by the plasma heparin thrombin time. Acta haemat. (Basel) 23: 195 1960;
• 24 Howell W. H, Holt E. Two new factors in blood coagulation - heparin and pro-antithrombin. Amer. J. Physiol. 47: 328 1918;
• 25 Ivy A. G, Nelson D, Bûcher G. The standardization of certain factors in the cutaneous “venostasis” bleeding time technique. J. Lab. clin. Med. 26: 1812 1941;
• 26 Jacobsson K. Studies on the determination of fibrinogen in human blood plasma. Scand. J. clin. Lab. Invest.. 7, Suppl. 14 1955
• 27 Klein P. D, Seegers W. H. The nature of plasma antithrombin activity. Blood 5: 742 1950;
• 28 Lasch H. G, Rodriguez-Erdmann F, Schimpf K. Antithrombin III und Anti - Blutt hrombo -kinase bei experimenteller Verbrauchskoagulopathie. Klin. Wschr. 39: 645 1961;
• 29 Lewis J. H, Walters D, Didisheim P, Merchant W. R. Application of continuous flow electrophoresis to the study of the blood coagulation proteins and the fibrinolytic enzyme system. I. Normal human materials. J. clin. Invest. 37: 1323 1958;
• 30 Loeb J. Le cof acteur plasmati que de l’héparine et ses rapports avec l’antithrombine. Arch. Sci. physiol. 10: 129 1956;
• 31 Loeliger E. A, Hers J. F. Ph. Chronic antithrombinaemia (antithrombin V) with haemorrhagic diathesis in a case of rheumatoid arthritis with hypergammaglobulinemia. Thrombos. Diathes. haemorrh. (Stuttg.) 1: 499 1957;
• 32 Lyttleton J. W. The antithrombin activity of heparin. Biochem. J. 58: 15 1954;
• 33 Markwardt F, Walsmann P. Untersuchungen über den Mechanismus der Antithrombin-Wirkung des Heparins. Hoppe-Seylers Z. physiol. Chem. 317: 64 1959;
• 34 Monkhouse F. G. Relationship between antithrombin and thrombin levels in plasma and serum. Amer. J. Physiol. 197: 984 1959;
• 35 Monkhouse F. C, Milojevic S. Changes in thrombin generation and antithrombin titer following massive bleeding and transfusion in dogs. Canad. J. Biochem. 38: 475 1960;
• 36 Niewiarowski S, Kowalski E. Un nouvel anticoagulant derivé du fibrinogène. Rev. Hémat. 15: 320 1958;
• 37 Nygaard K. Direct method of counting platelets in oxalated blood. Proc. Mayo Clin. 8: 365 1933;
• 38 Owren P. A. The coagulation of blood. Investigations on a new clotting factor. Acta med. scand.. 128, Suppl. 194 1947
• 39 Poller L. The pathogenesis of thrombosis. Postgraduate Med. J. 36: 564 1960;
• 40 Quick A. J. The normal antithrombin of the blood and its relation to heparin. Amer. J. Physiol. 123: 712 1938;
• 41 Quick A. J, Fauvre-Gilly J. E. Fibrin: A factor influencing the consumption of prothrombin in coagulation. Amer. J. Physiol. 158: 387 1949;
• 42 Seegers W. H. Prothrombin. 312 Harvard Univ. Press; Cambridge: 1962
• 43 Seegers W. H, Johnson J. F, Fell C. The antithrombin reaction related to prothrombin activation. Amer. J. Physiol. 176: 97 1954;
• 44 Seegers W. H, Miller K. D, Andrews E. B, Murphy R. G. Fundamental interactions and effect of storage, ether, adsorbants and blood clotting on plasma antithrombin activity. Amer. J. Physiol. 109: 700 1952;
• 45 Seegers W. H, Nieft M, Loomis E. C. Note on the adsorption of thrombin on fibrin. Science 101: 520 1945;
• 46 Seegers W. H, Warner E. D, Brinkhous K. M, Smith H. P. Heparin and the antithrombin activity of plasma. Science 96: 300 1942;
• 47 Soulier J. P. Le test de tolerance á l’héparine dans le controle des traitement anticoagulants par la dicoumarine et ses analogues. Thrombosis and embolism. 793 Schwabe & Co.; Basel: 1955
• 48 Stefanini M, Dameshek W. The hemorrhagic disorders. Grune & Stratton; New York: 1955
• 49 Volkert M. Studies on the antithrombin content of the blood and its relation to heparin. Acta physiol. scand.. 5, Suppl. 15 1942
• 50 Waaler B. A. Contact activation in the intrinsic blood clotting system. Scand. J. clin. Lab. Invest.. 11, Suppl. 37 1959
• 51 Waugh T. R, Ruddick D. W. A test for increased coagulability of the blood. Canad. M. A. J. 50: 547 1944;